Building on the Promise of Cancer Vaccines for Solid Tumors
Abstract
A novel telomerase vaccine (INVAC-1) has been evaluated in a phase I clinical trial (n = 26). It induced CD8+ and CD4+ T-cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3206
Entities
People
- Craig L. Slingluff Jr
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- University of Virginia